Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00625443 · ClinicalTrials.gov registry record · Phase 2
Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
A Phase 2 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT00625443 is a Phase 2 study that has completed, run by Eisai. The registered enrollment target is 53 participants.
The verdict
NCT00625443, a Phase 2 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of AKR-501 (avatrombopag) administered in participants with chronic Idiopathic Thrombocytopenic Purpura (ITP) who were enrolled into and completed 28 days of study treatment in Protocol 501-CL-003 (NCT00441090).
Interventions
- DRUG Blinded (placebo)
- DRUG Open Label (Avatrombopag tablets)
- DRUG Blinded (Avatrombopoag tablets)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2007-05 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00625443
The ClinicalTrials.gov registry entry for NCT00625443 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Blinded (placebo) is the first listed.
NCT00625443 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00625443 about?
NCT00625443 is a clinical study titled "Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003". The purpose of this study is to determine the safety and efficacy of AKR-501 (avatrombopag) administered in participants with chronic Idiopathic Thrombocytopenic Purpura (ITP) who were enrolled into and completed 28 days of study treatment in Protocol 501-CL-003 (NCT00441090).
What is the current status of trial NCT00625443?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2007-05. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00625443?
The interventions under investigation include: Blinded (placebo) (DRUG), Open Label (Avatrombopag tablets) (DRUG), Blinded (Avatrombopoag tablets) (DRUG).
Who is sponsoring clinical trial NCT00625443?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.